Maria Carmen Affinita

ORCID: 0000-0003-1680-0240
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Sarcoma Diagnosis and Treatment
  • Tumors and Oncological Cases
  • Testicular diseases and treatments
  • Neuroendocrine Tumor Research Advances
  • Cancer Diagnosis and Treatment
  • Neuroblastoma Research and Treatments
  • Cancer Genomics and Diagnostics
  • Renal cell carcinoma treatment
  • Acute Lymphoblastic Leukemia research
  • Renal and related cancers
  • Surgical site infection prevention
  • Childhood Cancer Survivors' Quality of Life
  • Urological Disorders and Treatments
  • Cancer Cells and Metastasis
  • Cancer therapeutics and mechanisms
  • Bone and Joint Diseases
  • Bone Tumor Diagnosis and Treatments
  • Soft tissue tumor case studies
  • Medical Imaging and Pathology Studies
  • Epigenetics and DNA Methylation
  • CAR-T cell therapy research
  • Folate and B Vitamins Research
  • Cardiac tumors and thrombi
  • Intraperitoneal and Appendiceal Malignancies
  • Colorectal and Anal Carcinomas

University of Padua
2017-2025

Azienda Ospedaliera di Padova
2024

University of Naples Federico II
2015-2016

University of Campania "Luigi Vanvitelli"
2011-2016

Schimke immuno-osseous dysplasia (SIOD) is a rare multisystemic disorder with variable clinical expressivity caused by biallelic variants in SMARCAL1. A phenotype–genotype correlation has been attempted and of SMARCAL1 may be associated environmental genetic disturbances gene expression. We describe two siblings born from consanguineous parents diagnosis SIOD revealed whole exome sequencing (WES). Results: homozygous missense variant the (c.1682G>A; p.Arg561His) was identified both...

10.3390/ijms21228604 article EN International Journal of Molecular Sciences 2020-11-15

Liquid biopsy analysis represents a powerful and noninvasive tool to uncover biomarkers for disseminated disease assessment longitudinal monitoring of patients. Herein, we explored the value circulating tumor cells (CTC DTC, respectively) cell‐free DNA (cfDNA) in pediatric rhabdomyosarcoma (RMS). Peripheral blood bone marrow samples were analyzed detect enumerate CTC respectively. We used epithelial cellular adhesion molecule (EpCAM)‐based CellSearch platform coupled with an automatic device...

10.1002/1878-0261.13197 article EN cc-by Molecular Oncology 2022-02-25

Abstract Background In certain rare undifferentiated small round cell sarcomas new specific molecular CIC‐DUX4 /other partner, BCOR‐CCNB3 YWHAE fusions, or BCOR‐ITD (internal tandem duplication) were identified. These “ CIC fused ” (CIC‐fused/ ATXN1::NUTM1 ) and BCOR rearranged (BCOR fused/ITD/ soft tissue (STS) are not well described. Methods Multi‐institutional European retrospective analysis of young patients (0–24 years) with CIC‐fused STS. Results Overall, out the 60 selected, fusion...

10.1002/cam4.6113 article EN cc-by Cancer Medicine 2023-05-22

After the completion of therapy, patients with localized rhabdomyosarcoma (RMS) are subjected to intensive radiological tumor surveillance. However, clinical benefit this surveillance is unclear. This study retrospectively analyzed value off-therapy by comparing survival in whom relapse was detected routine imaging (the group) and first suspected symptoms symptom group).This included relapsed RMS after therapy for who were treated large pediatric oncology hospitals France, United Kingdom,...

10.1002/cncr.32603 article EN cc-by-nc Cancer 2019-11-21

T-cell Acute Lymphoblastic Leukemia (ALL) represents about 10-15 % of pediatric ALL cases. EZH2, one the components Polycomb group proteins (PRC2) complex, catalyzes trimethylation histone H3 lysine 27 that is associated with transcriptional repression and tumor development.We examined expression levels PRC2 complex in primary samples T cells at diagnosis by western blotting real time PCR. We evaluated effect 3-deazaneplanocin-A (DZNep), an EZH2 inhibitor, alone combination Daunoblastine on...

10.1186/s13046-015-0191-0 article EN cc-by Journal of Experimental & Clinical Cancer Research 2015-08-13

Malignant peripheral nerve sheath tumor (MPNST) is one of the most common nonrhabdomyosarcoma soft tissue sarcomas encountered in pediatric age, and it generally characterized by poor outcome, particularly for relapsing patients.This study considered 73 patients <21 years age with MPNST observed among 120 enrolled Italian protocols from 1979 to 2004. With aim possibly establishing a risk-adapted stratification, patients' outcome was examined using univariate multivariate analysis based on...

10.1002/pbc.26816 article EN Pediatric Blood & Cancer 2017-09-19

Abstract Background Rhabdomyosarcoma (RMS) occurring at nonparameningeal head and neck (NPM‐HN) sites carries a better prognosis than parameningeal RMS some other sites. We analyzed the treatments administered results obtained in patients with localized NPM‐HN RMS, included protocols coordinated by Italian Soft Tissue Sarcoma Committee (STSC), an effort to identify prognostic factors that could facilitate tailoring of treatment. Methods Sixty‐six up 18 years age previously untreated, were...

10.1002/pbc.26876 article EN Pediatric Blood & Cancer 2017-11-08

Rhabdomyosarcoma is a soft tissue malignant musculoskeletal tumor frequent in children. Biliary duct localization extremely rare, but it the most common cause of obstructive jaundice pediatric patients.This report describes series 10 patients under 18 years age with biliary tract rhabdomyosarcoma who were enrolled, from 1979 to 2004, 3 consecutive Italian cooperative protocols that had been drawn up by Soft Tissue Sarcoma Committee Associazione Italiana Ematologia Oncologia Pediatrica...

10.5301/tj.5000692 article EN Tumori Journal 2017-12-01

Enhancer of Zeste Drosophila Homologue 2 (EZH2) is a key regulator transcription as member polycomb repressive complex (PRC2) which exerts repression downstream genes and correlated to invasiveness progression different tumours. Therefore, we evaluated the expression PRC2 proteins in pediatric soft tissue sarcoma (rhabdomyosarcoma, RMS extraosseous Ewing sarcoma, EES) correlating them clinical outcome patients.We analyzed protein by quantitative real time PCR, western blotting...

10.1186/s12935-016-0338-x article EN cc-by Cancer Cell International 2016-07-27

Osteonecrosis is a significant adverse effect of treatment administered to children suffering from acute lymphoblastic leukemia (ALL) that may have negative on the quality life. The purpose this study evaluate rate secondary vascular osteonecrosis (ON) in population pediatric patients with ALL treated corticosteroids and cytostatic agents. A retrospective analysis prospectively collected data medical records 328 identified 4 cases ON, corresponding 1.2% all observed. Of our 3 were girls 1...

10.4081/pmc.2016.118 article EN cc-by-nc La Pediatria Medica e Chirurgica 2016-11-28

High-dose methotrexate (MTX) is a key component of most treatment protocols for childhood and adolescent non-Hodgkin lymphoma (NHL). Recent studies have suggested that the toxicity antifolate drugs, such as MTX, affected by inherited single nucleotide polymorphisms (SNPs) in folate metabolizing genes. The aim our study was to investigate potential influence C677T A1298C genetic variants methylenetetrahydrofolate reductase (MTHFR) gene on clinical efficacy MTX pediatric patients with NHL (n =...

10.3109/10428194.2013.784758 article EN Leukemia & lymphoma/Leukemia and lymphoma 2013-03-14

Abstract Introduction The treatment paradigm in desmoid‐type fibromatosis (DF) has changed recent years from a surgery‐based strategy to multidisciplinary approach that includes systemic therapies. Among various medical therapies, hydroxyurea been considered of potential interest. This case series summarizes the experience gained at four centers using relapsing DF. Methods Eligibility requirements were age &lt; 21 years, histologically confirmed DF, and progressive or recurrent disease after...

10.1002/pbc.27472 article EN Pediatric Blood & Cancer 2018-09-30

Abstract Background Irinotecan is a drug active against pediatric sarcomas with toxicity profile that theoretically allows for its association more myelotoxic drugs. We examined the feasibility of dose‐density strategy integrating irinotecan in standard chemotherapy regimens patients high‐risk sarcomas. Methods Between November 2013 and January 2020, 23 ≤25 years old were included study. Eleven newly diagnosed metastatic disease received nine cycles IrIVA...

10.1002/pbc.28951 article EN Pediatric Blood & Cancer 2021-03-10

Introduction: From 2002 to 2011, the Italian Soft Tissue Sarcoma Committee explored a combination of topotecan and carboplatin as second-line strategy for children with resistant or relapsing rhabdomyosarcoma. Methods: Patients received two blocks 2 mg/m on days 1, 2, 3, 250 4 5, followed by alternating topotecan–cyclophosphamide carboplatin–etoposide total six courses 3-week intervals. Tumor response was assessed after cycles, local control implemented when feasible. Results: A 38 patients...

10.1177/0300891618792479 article EN Tumori Journal 2018-08-22

The literature widely supports the benefits of early integration palliative care into pediatric oncological care; however, many barriers to its successful remain. Integrating as possible in oncology pathway is critical, but other criteria are relevant positive results. This paper aims contribute early/late referral dualism (PPC) and highlight importance a collaborative approach between oncologists teams. study investigates impact versus late PPC, intersecting it with synergy work services...

10.3389/fonc.2024.1397983 article EN cc-by Frontiers in Oncology 2024-07-25

Abstract Background The prognosis for patients with relapsed rhabdomyosarcoma (RMS) depends on a number of variables, including tumor characteristics, type relapse, and treatment received. All published studies have considered characteristics at initial diagnosis, but not the time recurrence. In this study, we compared diagnosis moment local relapse to better define chance cure in group patients. Methods We first analyzed 92 children localized RMS treated according RMS96 RMS2005 protocols...

10.1002/pbc.28674 article EN Pediatric Blood & Cancer 2020-08-29

Abstract Purpose To evaluate clinical features at diagnosis, prognostic factors, and outcomes of malignant sacrococcygeal germ cell tumors (SC‐GCTs) in patients enrolled the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) TCG 2004 protocol. Patients Methods A prospective analysis was conducted on all consecutive diagnosed with SC‐GCTs between January May 2017. stage I underwent surgery subsequent surveillance, others received pediatric cisplatinum‐etoposide‐bleomycin (pPEB)...

10.1002/pbc.28812 article EN Pediatric Blood & Cancer 2020-11-21

Pediatric nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) may rarely occur in visceral tissues, and little is known about their clinical history. The present study retrospectively analyzed a group of patients prospectively registered Italian pediatric protocols conducted between 1979 2004.Inclusion criteria for the were as follows: pathological diagnosis "adult-type NRSTS," arising at sites (lung-pleurae, liver, kidney, mesentery-bowel); age under 18 years; no previous treatment except...

10.1002/pbc.26490 article EN Pediatric Blood & Cancer 2017-02-24

We describe three children who developed an osteosarcoma after receiving treatment for acute lymphoblastic leukemia, which included allogeneic bone marrow transplant (BMT). discuss the therapeutic options. None of patients responded to conventional chemotherapy, but one patient given regorafenib showed a temporary response. conclude that BMT has aggressive course and it is worth further investigating multikinase inhibitors in this setting.

10.1089/jayao.2020.0054 article EN Journal of Adolescent and Young Adult Oncology 2020-06-03

Inflammatory myofibroblastic tumors (IMTs) are locally aggressive malignancies occurring at various sites. Surgery is the mainstay of treatment and prognosis generally good. For children with unresectable or metastatic tumors, however, outcome particularly severe, limited also by lack predictive biomarkers therapy efficacy disease progression. Blood represents a minimally invasive source cancer for real-time assessment tumor growth, when it involves analysis circulating cells (CTC). As CTCs...

10.3389/fped.2021.652583 article EN cc-by Frontiers in Pediatrics 2021-04-29
Coming Soon ...